Skip to content

Acupuncture in the treatment of neovascular age-related macular degeneration: a randomized, open-label trial

Huoxue Tongluo acupuncture in the treatment of neovascular age-related macular degeneration: a randomized, open-label trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000361
Enrollment
Unknown
Registered
2024-09-03
Start date
2024-07-15
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration

Interventions

experimental group:acupuncture+Standard anti-VEGF therapy (3+PRN regimen)
Standard treatment group :Standard anti-VEGF therapy (3+PRN regimen)

Sponsors

Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) The age range is 50-80 years old; 2) Meets the diagnostic criteria for nAMD: (a) Reduced visual acuity. There is discoid exudation in the macular area with repeated hemorrhages visible neovascularization and loss of macular central recess reflex. (b) Fundus fluorescence angiography shows: neovascularization with fluorescence leakage and occluded fluorescence in the hemorrhagic area; (c) 3) Best corrected visual acuity between 4 and 73 letters (EDTRS) approximately equal to 20/32 to 20/800 on the Snellen visual acuity scale; 4) Those who are capable of signing informed consent.

Exclusion criteria

Exclusion criteria: (1) A history of diabetic retinopathy retinal vein occlusion iridocyclitis macular tear retinal detachment and macular proptosis; (2) History of glaucoma history of ocular trauma; (3) History of vitreous surgery and PDT treatment; (4) Received anti-VEGF treatment 6 months before enrollment. (5) Combined with serious cardiac cerebrovascular hepatic and renal systemic diseases long-term use of anticoagulant drugs and coagulation disorders; (6) Patients with a history of metal allergy to acupuncture needles; patients with a history of needle-sickness; (7) Patients who are allergic to anti-VEGF drugs; (8) Patients with cognitive impairment who are unable to detect vision; (9) Pregnant women and those preparing for pregnancy; (10) Patients who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
best-corrected visual acuity;

Secondary

MeasureTime frame
incidence of subretinal fibrosis in one year;central macular thickness;

Countries

china

Contacts

Public Contactwusun

Xiyuan Hospital, China Academy of Chinese Medical Sciences

18717123259@163.com17801223057

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026